| NCT05754684 | Hong Kong Children´s Hospital|The University of Hong Kong | Neuroblastoma Recurrent | 2022-01-01 | PHASE2 |
| NCT07318831 | Tianjin Medical University Cancer Institute and Hospital | Neuroblastoma (NB)|Neuroblastoma in Children | 2025-12-31 | PHASE2 |
| NCT06172296 | National Cancer Institute (NCI) | Ganglioneuroblastoma, Nodular|Neuroblastoma | 2024-04-19 | PHASE3 |
| NCT00026312 | National Cancer Institute (NCI) | Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma | 2001-10-26 | PHASE3 |
| NCT02743429 | University Medicine Greifswald|Children´s Cancer Research Institute, Austria | Neuroblastoma | 2015-03-27 | PHASE2 |
| NCT05373901 | BeiGene | High-risk Neuroblastoma | 2022-06-07 | PHASE1 |
| NCT01767194 | National Cancer Institute (NCI)|United Therapeutics | Ganglioneuroblastoma|Recurrent Neuroblastoma | 2013-02-12 | PHASE2 |
| NCT07375563 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Neuroblastoma (NB)|Ganglioneuroblastoma | 2025-11-19 | PHASE3 |
| NCT06485947 | Princess Maxima Center for Pediatric Oncology|EUSA Pharma, Inc. | Neuroblastoma | 2025-01-28 | PHASE1 |
| NCT05080790 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|RECORDATI GROUP | Leiomyosarcoma | 2021-11-15 | PHASE2 |
| NCT04211675 | Nationwide Children´s Hospital | Relapsed Neuroblastoma|Refractory Neuroblastoma | 2022-09-01 | PHASE1|PHASE2 |
| NCT05400603 | Emory University | Neuroblastoma|Refractory Neuroblastoma|Relapsed Neuroblastoma|Relapsed Osteosarcoma|Refractory Osteosarcoma | 2023-11-06 | PHASE1 |
| NCT03786783 | National Cancer Institute (NCI) | Ganglioneuroblastoma|High Risk Neuroblastoma | 2019-03-04 | PHASE2 |
| NCT07261241 | New Approaches to Neuroblastoma Therapy Consortium|United Therapeutics|Jubilant DraxImage Inc. | Neuroblastoma | 2026-07-31 | PHASE2 |
| NCT03794349 | Children´s Oncology Group|National Cancer Institute (NCI) | High Risk Neuroblastoma|Recurrent Neuroblastoma|Refractory Neuroblastoma | 2019-07-08 | PHASE2 |
| NCT05421897 | Children´s Hospital Los Angeles|United Therapeutics | Neuroblastoma | 2022-11-29 | PHASE1 |
| NCT04385277 | Children´s Oncology Group|National Cancer Institute (NCI) | Ganglioneuroblastoma, Nodular|Neuroblastoma | 2020-12-31 | PHASE2 |
| NCT04238819 | Eli Lilly and Company | Relapsed Solid Tumor|Refractory Solid Tumor | 2020-11-09 | PHASE1|PHASE2 |
| NCT07334301 | University of Birmingham | Relapsed Neuroblastoma | 2024-11-11 | PHASE1|PHASE2 |
| NCT06669013 | N.N. Petrov National Medical Research Center of Oncology | Bone Sarcoma|Embryonal Rhabdomyosarcoma|Alveolar Rhabdomyosarcoma | 2021-05-20 | PHASE3 |
| NCT04751383 | National Cancer Institute (NCI) | High Risk Neuroblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Neuroblastoma|Resectable Osteosarcoma | 2021-08-31 | PHASE1 |
| NCT07437963 | National Cancer Institute (NCI) | Recurrent Ganglioneuroblastoma|Recurrent Neuroblastoma|Refractory Ganglioneuroblastoma|Refractory Neuroblastoma | 2026-07-30 | PHASE1|PHASE2 |
| NCT01041638 | National Cancer Institute (NCI) | High Risk Neuroblastoma | 2009-12-21 | PHASE3 |
| NCT02484443 | National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in the Lung|Metastatic Osteosarcoma|Recurrent Osteosarcoma | 2016-02-04 | PHASE2 |
| NCT01711554 | National Cancer Institute (NCI) | Recurrent Neuroblastoma|Refractory Neuroblastoma | 2013-02-04 | PHASE1 |
| NCT04221035 | Gustave Roussy, Cancer Campus, Grand Paris | High-Risk Neuroblastoma|Patient With Insufficient Response Chemoimmunotherapy | 2019-11-05 | PHASE3 |
| NCT06450041 | New Approaches to Neuroblastoma Therapy Consortium|Nationwide Children´s Hospital|United Therapeutics|Children´s Neuroblastoma Cancer Fund | Neuroblastoma | 2024-12-16 | PHASE2 |
| NCT02308527 | University of Birmingham|Cancer Research UK|Roche Pharma AG|Imagine for Margo|EUSA Pharma, Inc. | Neuroblastoma | 2013-07 | PHASE2 |
| NCT05558280 | Prof. Franca Fagioli | Osteosarcoma in Children | 2023-11-30 | PHASE2 |
| NCT03332667 | New Approaches to Neuroblastoma Therapy Consortium|United Therapeutics|National Cancer Institute (NCI) | Neuroblastoma | 2018-09-12 | PHASE1 |
| NCT02573896 | New Approaches to Neuroblastoma Therapy Consortium|Nationwide Children´s Hospital|United Therapeutics | Neuroblastoma | 2019-01-14 | PHASE1 |
| NCT02693171 | United Therapeutics | Neuroblastoma | 2016-03-15 | |
| NCT02641782 | University of Cologne | Neuroblastoma | 2015-11 | PHASE2 |
| NCT00005576 | National Cancer Institute (NCI) | Disseminated Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma | 2001-01 | PHASE1 |
| NCT01592045 | United Therapeutics | Neuroblastoma | 2012-08 | PHASE1|PHASE2 |
| NCT00030719 | University of Leicester | Neuroblastoma | 2001-12 | PHASE3 |